Cantor Fitzgerald Research Analysts Boost Earnings Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research note issued on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will earn $37.72 per share for the year, up from their previous forecast of $37.66. Cantor Fitzgerald currently has a “Neutral” rating and a $925.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $38.80 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the firm posted $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year.

Several other equities research analysts also recently weighed in on REGN. Barclays increased their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Finally, TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $906.54 on Tuesday. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a 50 day moving average of $950.58 and a 200 day moving average of $893.29. The firm has a market cap of $99.50 billion, a PE ratio of 26.09, a PEG ratio of 2.59 and a beta of 0.11.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in REGN. FMR LLC grew its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the period. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after acquiring an additional 39,780 shares in the last quarter. Capital World Investors increased its holdings in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares in the last quarter. Putnam Investments LLC raised its position in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after purchasing an additional 34,326 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the transaction, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders sold a total of 11,022 shares of company stock worth $10,552,991 in the last 90 days. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.